Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors

Authors :: Richard W. Joseph
Svetomir N. Markovic
Chengwei Peng
Lisa A. Kottschade
Igor Puzanov
Jeffrey A. Sosman
Alan H. Bryce
Roxana S. Dronca
Amanda Shreders
Douglas B. Johnson
Source :: Journal of Clinical Oncology. 33:e20045-e20045
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e20045 Background: Elevated lactate dehydrogenase (LDH) is a known negative prognostic marker in patients (pts) with metastatic melanoma (MM) and may predict lack of response to anti-PD-1/PD-L1 age...

Subjects :: Cancer Research
Pathology
medicine.medical_specialty
Metastatic melanoma
business.industry
chemistry.chemical_compound
Oncology
chemistry
Elevated lactate dehydrogenase
Lactate dehydrogenase
Cancer research
medicine
In patient
business

Tools